{
    "clinical_study": {
        "@rank": "85762", 
        "arm_group": [
            {
                "arm_group_label": "the first donor", 
                "description": "the original donor applicable patients were assigned to receive the first donor's stem cell treatment after G-CSF mobilization or combination chemotherapy"
            }, 
            {
                "arm_group_label": "the second donor", 
                "description": "HLA-mismatched, the second donor's stem cell infusion"
            }
        ], 
        "biospec_descr": {
            "textblock": "the blood and bone marrow samples before and after transplantation and DSI"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The relapse leukemia patients after transplantation were divided into two groups randomly.\n      Group D1: patients received first-donor stem cells infusion(DSI) treatment with or without\n      chemotherapy; group D2: patients received second-donor DSI treatment with or without\n      chemotherapy. The second donors were preferably donors who were genetically related and had\n      more HLA-match locus. The re-induction chemotherapy regimen was primarily MAT(mitoxantrone,\n      cytarabine, Teniposide ) for acute myeloid leukemia (AML) and VMCLD(vincristine, Teniposide,\n      cyclophosphamide, L-Asparaginase, Dexamethasone) for acute lymphocytic leukemia (ALL), and\n      no graft versus host disease(GVHD) prevention was conducted pre- and post- therapy."
        }, 
        "brief_title": "Randomized Study of HLA-mismatched DSI to Treat Relapse Leukemia After HLA- Matched Transplantation", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Relapse Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Recurrence"
            ]
        }, 
        "detailed_description": {
            "textblock": "Evaluation indications include bone marrow morphology,hematopoietic recovery (neutrophil and\n      platelet), 100-day transplantation-related mortality (TRM), donor chimerism, acute GVHD,\n      chronic GVHD, disease free survival (DFS), and overall survival (OS). The cut-time of the\n      follow-up was Oct, 2013. DFS was defined as the time between the date of transplantation to\n      the death or relapse. OS was defined as the time from diagnosis to death or to the last date\n      of follow-up until Oct. 2013."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Eligible patients were between 9 and 67 years of age with de novo diagnosed or\n             treated-related  Acute leukemia relapsed after HLA-matched hematological stem cell\n             transplantation from Feb 2005 to Feb 2013\n\n          -  Relapse was morphologically and molecularly  diagnosed,with the help of cytogenetic\n             and engraftment.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status was 0 to 2\n\n        Exclusion Criteria:\n\n          -  Patients without receiving CR will not receive further post-remission trial therapy\n\n          -  The patients of AML-M3 were excluded from this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "67 Years", 
            "minimum_age": "9 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Eligible patients were between 9 and 67 years of age with de novo diagnosed or\n        treated-related  Acute leukemia relapsed after HLA-matched hematological stem cell\n        transplantation from Feb 2005 to Feb 2013."
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02028650", 
            "org_study_id": "RL13-307PLAH-AHS"
        }, 
        "intervention": [
            {
                "arm_group_label": "the first donor", 
                "description": "HLA-matched stem cell infusion", 
                "intervention_name": "the first donor's stem cell", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "the second donor", 
                "description": "HLA-mismatched, the second donor's stem cell infusion", 
                "intervention_name": "the second donor's stem cell", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "relapse leukemia", 
            "DSI"
        ], 
        "lastchanged_date": "January 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100071"
                }, 
                "name": "Affiliated Hospital of Academy of Military Medical Sciences"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "2", 
        "official_title": "HLA-mismatched Peripheral Hematopoietic Stem Cells Infusion in the Treatment of Leukemia Patients Relapse After HLA- Matched Allogeneic Stem Cell Transplantation: A Randomized Clinical Trial", 
        "overall_official": {
            "affiliation": "Affiliated Hospital of Academy of Military Medical Sciences", 
            "last_name": "qiao jianhui, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: National Natural Science Foundation", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants with graft versus host diseases", 
            "safety_issue": "Yes", 
            "time_frame": "100 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02028650"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The Affiliated Hospital of the Chinese Academy of Military Medical Sciences", 
            "investigator_full_name": "huishengai", 
            "investigator_title": "director of Hematology Department", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Time to Disease Progression", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "source": "The Affiliated Hospital of the Chinese Academy of Military Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "huishengai", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2005", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}